← Evidence map

ArticleWorld journal of urology2025

Combined neoadjuvant and adjuvant therapy versus adjuvant therapy in high-risk upper tract urothelial carcinoma: a propensity matched multicenter analysis (ROBUUST 2.0 International Collaborative Group).

Ahmed Eraky et al.PubMed ↗Publisher ↗

No numbers read from the abstract.

1 paper cites it

2025

this papercites it

Combined neoadjuvant and adjuvant therapy versus adjuvant therapy in high-risk upper tract urothelial carcinoma: a propensity matched multicenter analysis (ROBUUST 2.0 International Collaborative Group). | OpenQuestion